Vertex Pharmaceuticals VRTX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's pre-tax income?
- Vertex Pharmaceuticals (VRTX) reported pre-tax income of $1.25B in Q1 2026.
- How has Vertex Pharmaceuticals's pre-tax income changed year-over-year?
- Vertex Pharmaceuticals's pre-tax income increased by 71.5% year-over-year, from $730.4M to $1.25B.
- What is the long-term trend for Vertex Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's pre-tax income has grown at a 14.2% compound annual growth rate (CAGR), from $2.73B to $4.64B.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.